Lung adenocarcinoma (LUAD or LAC), is a major histological subtype of lung cancer 1,2 and one of the most common malignant tumors with high incidence and mortality. Lack of typical symptoms and signs in the early stages, patients with LUAD often progress to advanced stages at the time of diagnosis. 3 As higher stage tumors with higher rates of recurrence, there is a significant proportion of patients with LUAD less than 5-year survival. 4-6 Therefore, besides histological classification, it is urgently need to develop novel molecular prognostic signature for predicting the risk of disease recurrence and identifying high-risk subgroup of patients with LUAD who might benefit from adjuvant treatment.
biomarkers. Protein-coding genes (PCGs) are the most common biomarkers and involved in the many key biological processes which can be powerful predictors of survival in patients in different cancers. [7] [8] [9] [10] Recently, long non-coding RNAs (lncRNAs) are transcripts >200 nucleotides with little coding capacity. Long non-coding RNA (lncRNA) becomes new participant in tumorigenesis due to their various functions in a variety of cancer gene regulatory mechanisms, and has important clinical implications in terms of prognosis. [7] [8] [9] [10] [11] [12] [13] [14] Recent studies have constructed many lncRNA signature [15] [16] [17] to predict the prognosis of patients. For instance, a 3-lncRNA signature can be a new biomarker for the esophageal squamous cell carcinoma prognosis, 18 an immune-related 6-lncRNA signature could improve prognosis prediction of glioblastoma multiforme 19 and a potential signature of eight long non-coding RNAs could predict survival in patients with non-small cell lung cancer. 20 The advantage of combining PCGs with lncRNAs as prognostic markers is to show the disorder alteration of patients with cancer in greater detail from multiple dimensions. 14, [21] [22] [23] Here, we analyzed PCG and lncRNA expression profiles of LUAD from Gene Expression Omnibus and developed a multidimensional transcriptome prognostic signature to predict LUAD survival.
| MATERIAL S AND ME THODS

| Expression data of LUAD patients
We acquired the expression data and associated clinical information of patients with LUAD from Gene Expression Omnibus (GEO, https ://www.ncbi.nlm.nih.gov/geo/). Then, we performed a probe re-annotation pipeline to get both PCG and lncRNA expression data. Specifically, we downloaded GPL570 probe sequences from Affymetrix (http://www.affym etrix.com) website and aligned these probe sequences to the human lncRNA and PCG transcript sequences from GENCODE (http://www.genco degen es.org/), using BLASTn by the followed steps:(a) only retained the probes that matched to one PCG or lncRNA transcript. (b) Removed the probes matched to more than one transcript. (c) Each transcript should be perfectly matched to more than three probes. 24 
| Construction of a prognostic signature in the training dataset
Survival-related PCGs and lncRNAs in training dataset were screened out by cox proportional hazards regression analysis (P < .05). In an effort to make the dataset manageable, we used the random survival forests-variable hunting (RSFVH) algorithm to filter genes until nine PCGs and lncRNAs. 18 Subsequently, in order to further identify the prognostic genes, multivariable cox regression analysis was performed and a model to estimate prognosis risk was constructed as follows 17 :
N is the number of prognostic genes, ExpVluei is the expression value of lncRNAs, and β i is the estimated regression coefficient of ln-cRNAs in the Cox proportional hazards regression analysis. Each patient was assigned 511 risk scores, since nine genes form 2 9 −1 = 511 combinations. We chose prognostic signatures with AUC > 0.7 and log-rank P < .05 from all 511 combinations, which were calculated by ROC and Kaplan-Meier (KM) analysis.
| Statistical analysis and bioinformatics prediction analysis of the prognostic genes function
Utilizing the ROC and the timeROC analysis, we compared the predictive efficacy of pathological stage with that of the PCG-lncRNA signature. Cox proportional hazards regression analysis was performed to test whether the signature was an independent prognostic indicator, with significance defined as P < .05. All analyzes were performed using R program (www.r-proje ct.org), including timeROC, survival, and randomforestSRC (downloaded from Bio-conductor).
The co-expressed relationships between PCGs and lncRNAs of the selected signature and all other protein-coding genes were computed using Pearson's test; values with P < .05 and an absolute value of the Pearson coefficient > 0.3 were selected. We used the R package clusterProfiler to make Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment. 25 
| RE SULTS
| Patient characteristics and expression profiles
Expression profiles of 417 samples, along with corresponding clinical data of patients diagnosed with LUAD, were downloaded from GSE31210, GSE37745, and GSE30219. The median age of the LUAD patients was 61 years (30-83 years), and all patients were categorized as stage I, II, III, or IV (Table 1) . Then, GSE31210 (n = 226) and GSE37745 (n = 106) were served as training sets while GSE30219 (n = 85) dataset was validation set.
TA B L E 1 Summary of patient demographics and clinical characteristics
| Identification of prognostic genes from the training dataset
Through probe reannotating the Affymetrix Human Genome 
| Construction of the prognostic multi-gene signature in the training dataset
The seven PCGs and two lncRNAs could generate 2 9 −1 = 511 signatures, and each signature corresponded to a risk score
(ExpVluei × i )); detailed in Methods). ROC analyzes were performed on all 511 signatures and compared their AUC. The PCG-lncRNA combination composed of three PCG (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1) with the largest AUC (0.76) and minimum number of genes was selected ( Figure 1C ,D, Table 2 ). 
| The selected signature for survival prediction in the training and test datasets
In the training dataset, each patient was assigned a risk score by the prognostic model based on the PCG-lncRNA signature. As the median risk score as a cutoff point, patients from the training dataset were divided into a high-risk group (n = 113) and a low-risk group (n = 113).Then Kaplan-Meier survival analyzes were performed and found patients from the high-risk group had a significantly lower overall survival rate (OS) than those from the low-risk group (logrank test P < .001; Figure 2A ). When applied the median risk score to the GSE37745 and GSE30219 sets, patients from the two test sets were also divided into two groups, respectively, namely highrisk groups(n = 53/42) and low-risk groups (n = 53/43).Similarly, the survival of patients in the high-risk groups was significantly shorter than those in the low-risk groups (GSE37745 median 2.78, Figure 2C ).
According to the gene expression, risk score distribution and survival status of patients, Figure 3 illustrated the association of the gene expression with the survival. In the training dataset ( Figure 3A ), GSE37745 ( Figure 3B ), and GSE30219 ( Figure 3C ), patients with high expression of NHLRC2 and PLIN5 or low-risk scores had a higher probability of survival, and patients with high-risk scores or high-expressed AC087521.1 and GNAI3 had shorter survival time.
| The selected signature is an independent prognostic indicator
To better understand the clinical significance of the PCG-lncRNA signature in patients with LUAD, we also examined the association Table 3 ). Therefore, we performed a cox proportional hazards regression analysis to assess predictive independence of the PCG-lncRNA signature. The P values of the prognostic signature in the cox proportional hazards regression analysis from the training datasets were <.05, which showed that the PCG-lncRNA signature risk score was an independent prognostic indicator for patients with LUAD and was not affected by clinical features including sex, age, and pathologic stage (high-risk group vs low-risk group, HR = 15.79, 95% CI 3.70-67.33, P < .001, n = 226, Table 4 ). The independence of the PCG-lncRNA signature was validated in two test sets (high-risk group vs low-risk group, HR = 2.27, 95% CI 1.42-3.63, P < .001, n = 106/HR = 2.39, 95% CI 1.28-4.48, P = .01; Table 4 ). 
| Comparison of the survival prediction efficiency of the PCG-lncRNA signature with pathologic stage
Since GSE30219 without pathological stage information, we performed ROC analysis in two datasets (GSE31210/GSE37745, n = 226/106) to compare the survival prediction efficiency of pathological stage and the PCG-lncRNA signature. The AUC of the PCG-lncRNA signature was bigger than AUC of the pathological stage (Signature-AUC = 0.76/0.68 vs Stage-AUC = 0.65/0.62, Figure 4A,B) .
The high predictive efficacy demonstrated the PCG-lncRNA signature has important clinical significance.
TimeROC analysis was performed in the training dataset (n = 226), and we found that the AUC of the PCG-lncRNA signature was greater than the AUC of the pathological stage 
| Gene oncology and KEGG pathway enrichment analysis
To characterize the molecular function of lncRNAs and PCGs in the PCG-lncRNA signature, firstly, we screened out their co-expressed protein-coding genes from the GSE31210 and GSE37745 datasets and computed pearson correlation coefficients. Of these, 2654 protein-coding genes were highly correlated with at least one of the The PCG-lncRNA signature maintained its correlation with the overall survival rate when coupled with age, gender, and pathological stage as covariables. This suggests that the predictive power of the PCG-lncRNA signature is independent of these other In conclusion, using bioinformatics analysis, we identified a PCG-lncRNA signature composed of AC087521.1, GNAI3, NHLRC2, and PLIN5 that accurately predicted the overall survival of patients with LUAD based on three LUAD independent datasets. However, additional large-scale study is needed before the current results can be applied in clinical settings. 
